HK1213800A1 - 類毒素、組合物及相關方法 - Google Patents

類毒素、組合物及相關方法 Download PDF

Info

Publication number
HK1213800A1
HK1213800A1 HK16101854.5A HK16101854A HK1213800A1 HK 1213800 A1 HK1213800 A1 HK 1213800A1 HK 16101854 A HK16101854 A HK 16101854A HK 1213800 A1 HK1213800 A1 HK 1213800A1
Authority
HK
Hong Kong
Prior art keywords
methods
compositions
toxoid
related methods
inactivating
Prior art date
Application number
HK16101854.5A
Other languages
English (en)
Chinese (zh)
Inventor
Steven HAUSER
Original Assignee
Sanofi Pasteur, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur, Inc. filed Critical Sanofi Pasteur, Inc.
Publication of HK1213800A1 publication Critical patent/HK1213800A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK16101854.5A 2013-03-15 2014-03-14 類毒素、組合物及相關方法 HK1213800A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15
US61/790,423 2013-03-15
PCT/US2014/029035 WO2014144567A2 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (1)

Publication Number Publication Date
HK1213800A1 true HK1213800A1 (zh) 2016-07-15

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101854.5A HK1213800A1 (zh) 2013-03-15 2014-03-14 類毒素、組合物及相關方法

Country Status (13)

Country Link
US (2) US20160045586A1 (https=)
EP (1) EP2968507A2 (https=)
JP (1) JP2016516721A (https=)
KR (1) KR20150133770A (https=)
CN (1) CN105338997A (https=)
AR (1) AR095669A1 (https=)
AU (1) AU2014228956A1 (https=)
BR (1) BR112015023332A2 (https=)
CA (1) CA2907154A1 (https=)
HK (1) HK1213800A1 (https=)
SG (1) SG11201507608PA (https=)
TW (1) TWI624474B (https=)
WO (1) WO2014144567A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
AU2014277981B2 (en) 2013-06-14 2019-06-20 Sanofi Pasteur Inc. Compositions and methods of immunizing against C. difficile
WO2016187073A1 (en) * 2015-05-15 2016-11-24 Sanofi Pasteur Inc. Methods for immunizing against clostridium difficile
JP7349366B2 (ja) * 2017-06-09 2023-09-22 ヒプラ シエンティフィック エセ．エレ．ウ． クロストリジウム類毒素を含むワクチン
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2023107842A2 (en) * 2021-12-06 2023-06-15 Rutgers, The State University Of New Jersey Compositions and methods for treating cancer
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
EP2305303A3 (en) * 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
CA2694083A1 (en) 2007-07-26 2009-01-29 Sanofi Pasteur Limited Antigen-adjuvant compositions and methods
PL2198007T3 (pl) * 2007-09-14 2018-03-30 Sanofi Pasteur Biologics, Llc Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile
GB201011968D0 (en) * 2010-07-16 2010-09-01 Secr Defence Toxoiding method

Also Published As

Publication number Publication date
AR095669A1 (es) 2015-11-04
US20180028637A1 (en) 2018-02-01
KR20150133770A (ko) 2015-11-30
CN105338997A (zh) 2016-02-17
WO2014144567A2 (en) 2014-09-18
BR112015023332A2 (pt) 2017-08-22
CA2907154A1 (en) 2014-09-18
EP2968507A2 (en) 2016-01-20
US20160045586A1 (en) 2016-02-18
AU2014228956A1 (en) 2015-10-08
SG11201507608PA (en) 2015-10-29
TW201514197A (zh) 2015-04-16
WO2014144567A3 (en) 2014-12-04
TWI624474B (zh) 2018-05-21
JP2016516721A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
HK1213800A1 (zh) 類毒素、組合物及相關方法
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
AU2014241199A8 (en) Compositions and methods for enhancing plant growth
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
MX2011007983A (es) Composiciones de polimero que contienen absorbedores de ir nanoparticulas.
HK1208216A1 (en) Drug-conjugates, conjugation methods, and uses thereof
WO2014097099A3 (en) Glycoconjugation process
PH12019500989A1 (en) Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
WO2013006055A8 (en) A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
MX364712B (es) Composiciones sinergicas que comprenden etefona y saflufenacilo o ciclanilida y saflufenacilo.
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
TN2015000477A1 (en) A new bacterial lysobacter capsici strain and uses thereof
HK1225744A1 (zh) 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用
NZ709925A (en) Temperature stable cloquintocet-mexyl aqueous compositions
PH12014500175A1 (en) Maize plants having a partially or fully multiplied genome and uses thereof
PH12017501795A1 (en) Pestivirus vaccines for congenital tremors
WO2014205355A3 (en) Compositions and methods for clostridial transformation
MX2016000141A (es) El uso de piridonacarboxamidas seleccionadas o sales de las mismas como sustancias activas contra el estres abiotico de las plantas.
HK1213917A1 (zh) 類霉素、組合物及相關方法
WO2014009204A8 (de) Oxasilacyclen und verfahren zu deren herstellung
BR112012033213B8 (pt) Cassete de expressão, vetor incluindo um construto de arni e método de preparação de uma planta transgênica
WO2014184658A3 (en) Stable bubbles via particle absorption by electrostatic interaction
WO2014184659A3 (en) Bubble encapsulation via silicilic acid complexation